A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia ...
Contributing Writer for The Prospect Lily Hutcheson reflects on her fall break in London for a freshman seminar.
What keeps some immune systems youthful and effective in warding off age-related diseases? In a new paper published in ...
The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...
Charting the "dark matter" of the viral universe has implications not just for biotechnology—but potentially for battling the ...
We took a look around the SfN 2024 poster hall, picking our favorite posters and those we thought our audience would be most ...
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...
Have we entered the golden age of plant engineering?
EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback